Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech to Present at Upcoming Scientific Conferences
08:00am, Thursday, 30'th Apr 2026
PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Tuesday, 28'th Apr 2026
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:05am, Monday, 27'th Apr 2026
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
08:00am, Tuesday, 21'st Apr 2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
05:45pm, Thursday, 16'th Apr 2026
All three drugmakers have proven fairly innovative in their respective niches. Clinical and commercial progress could send their share prices soaring.
Could This Under-the-Radar Healthcare Stock Set You Up for Life?
12:37pm, Tuesday, 07'th Apr 2026
Krystal Biotech has attractive prospects within its core market. The biotech could launch more products in the next few years.
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
08:15am, Sunday, 29'th Mar 2026
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
12:31pm, Thursday, 19'th Mar 2026
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
12:45pm, Sunday, 22'nd Feb 2026
Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech po
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
12:25pm, Wednesday, 18'th Feb 2026
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up Following Better-Than-Expected Earnings
02:09am, Wednesday, 18'th Feb 2026
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) shares gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
03:54pm, Tuesday, 17'th Feb 2026
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology
03:02pm, Tuesday, 17'th Feb 2026
Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajec
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
07:00am, Tuesday, 17'th Feb 2026
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Str
Got $300? 2 Biotech Stocks to Buy and Hold Forever
05:48am, Monday, 16'th Feb 2026
Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.
